LEO Pharma presents new Real-World Evidence data at the 2024 Revolutionizing Atopic Dermatitis (RAD) Conference

- Data presentations cover findings relevant to real-world evidence in Adbry® (tralokinumab-ldrm) in the treatment of moderate to severe atopic dermatitis (AD).[1,2]

MADISON, New Jersey, June 11, 2024 – LEO Pharma A/S, a global leader in medical dermatology, presented new data on moderate to severe atopic dermatitis (AD) the 2024 Revolutionizing Atopic Dermatitis (RAD) Conference. The event was held from June 8 to 10 in Chicago, Illinois.

With two Health Economics and Outcome Research (HEOR) abstracts accepted for the meeting,[1,2] RAD - entirely focused on AD - offers a unique experience for LEO Pharma to engage in impactful discussions, innovative concepts, and foster evidence-based discourse through the insightful perspectives based in real-world evidence. With RAD's primary objective being the education of healthcare professionals and patients, real-world evidence is especially impactful.

"We are incredibly excited to have the opportunity to present Adbry real-world evidence at RAD. This conference provides us with a platform to share our latest findings and highlight our commitment to providing innovative solutions for those who need us most in medical dermatology," said Shannon Schneider, LEO Pharma Senior Medical Director. "Through our discussions and collaboration with fellow experts in the field of atopic dermatitis, we hope to help further the understanding and management of this complex condition."

The company's accepted presentations at the 2024 RAD Conference includes:

Tralokinumab

Real-world effectiveness of persistent tralokinumab use on clinician and patient-reported outcomes in patients with atopic dermatitis in the CorEvitas Atopic Dermatitis Registry
Author: **Jonathan Silverberg**, Sanjeev Balu, C. Jean Choi, Alvin Li, Oksana Pugach, Shannon Schneider, Eric Simpson
E-poster

Real-world baseline characteristics and persistence in adult patients initiating tralokinumab in the CorEvitas Atopic Dermatitis Registry
Author: **Eric Simpson**, Sanjeev Balu, C. Jean Choi, Alvin Li, Oksana Pugach, Shannon Schneider, Jonathan Silverberg
E-poster

Ends

About atopic dermatitis
Atopic dermatitis (AD) is a chronic, inflammatory skin disease characterized by intense itch and eczematous lesions.[3] Atopic dermatitis is the result of skin barrier dysfunction and immune dysregulation, leading to chronic inflammation.[4] Type 2 cytokines, including IL-13, play an important role in the key aspects of atopic dermatitis pathophysiology.[4,5]

About Adbry® (tralokinumab-ldrm)
Adbry® (tralokinumab-ldrm), which is marketed outside of the U.S. under the tradename Adtralza® (tralokinumab), is a high-affinity fully human monoclonal antibody developed to bind to and inhibit the

interleukin (IL)-13 cytokine, which plays a role in the immune and inflammatory processes underlying atopic dermatitis signs and symptoms.[4,5] Adbry specifically binds to the IL-13 cytokine, thereby inhibiting interaction with the IL-13 receptor α1 and α2 subunits (IL-13Rα1 and IL-13Rα2).[6]

Adbry is approved for the treatment of adults and pediatric patients (12 years and above) with moderate-to-severe AD in the U.S., Canada, the European Union, the United Arab Emirates, Great Britain, and South Korea. Adtralza is approved for use in adults with moderate-to-severe AD in Saudi Arabia, Switzerland, and Japan.

U.S. INDICATION AND IMPORTANT SAFETY INFORMATION

What is ADBRY?

- ADBRY (tralokinumab-ldrm) injection is a prescription medicine used to treat people 12 years of age and older with moderate-to-severe atopic dermatitis (eczema) that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies. ADBRY can be used with or without topical corticosteroids.

Do not use ADBRY if you are allergic to tralokinumab or to any of its ingredients.
What should I discuss with my healthcare provider before starting ADBRY?
Tell your healthcare provider about all your medical conditions, including if you:

- have eye problems.
- have a parasitic (helminth) infection.
- are scheduled to receive any vaccinations. You should not receive a “live vaccine” if you are treated with ADBRY.
- are pregnant or plan to become pregnant. It is not known whether ADBRY will harm your unborn baby. There is a pregnancy exposure registry for women who use ADBRY during pregnancy. The purpose of this registry is to collect information about the health of you and your baby You or your healthcare provider can get information and enroll you in this registry by calling 1-877-311-8972 or visiting https://mothertobaby.org/ongoing-study/adbry-tralokinumab/.
- are breastfeeding or plan to breastfeed. It is not known whether ADBRY passes into your breast milk and if it can harm your baby.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How should I use ADBRY?

- See the detailed “Instructions for Use” that comes with ADBRY for information on how to prepare and inject ADBRY and how to properly store and throw away (dispose of) used ADBRY prefilled syringes.
- Use ADBRY exactly as prescribed by your healthcare provider.
- Your healthcare provider will tell you how much ADBRY to inject and when to inject it.
- ADBRY comes as a single-dose (150 mg) prefilled syringe with needle guard.
- ADBRY is given as an injection under the skin (subcutaneous injection).
- If your healthcare provider decides that you or a caregiver can give the injection of ADBRY, you or your caregiver should receive training on the right way to prepare and inject ADBRY. Do not try to inject ADBRY until you have been shown the right way by your healthcare provider.
- If you miss a dose, inject the missed dose as soon as possible, then continue with your next dose at your regular scheduled time.
- If you inject -too much ADBRY than prescribed, call your healthcare provider or call Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away.
- Your healthcare provider may prescribe other medicines to use with ADBRY. Use the other prescribed medicines exactly as your healthcare provider tells you to.

What are the possible side effects of ADBRY?

ADBRY can cause serious side effects including:

- Allergic reactions (hypersensitivity), including a severe reaction known as anaphylaxis. Stop using ADBRY and tell your healthcare provider or get emergency help right away if you get any of the following symptoms:
  - breathing problems
  - itching
  - skin rash
  - swelling of the face, mouth, and tongue
  - fainting, dizziness, feeling lightheaded (low blood pressure)
  - hives
- Eye problems. Tell your healthcare provider if you have any worsening eye problems, including eye pain or changes in vision.

The most common side effects of ADBRY include:

- Upper respiratory tract infections
- Eye and eyelid inflammation, including redness, swelling, and itching
- Injection site reactions
- High count of a certain white blood cell (eosinophilia)

These are not all the possible side effects of ADBRY. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Please click here for full U.S. Prescribing Information, including Patient Information and Instructions for Use.

About LEO Pharma

LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities. LEO Pharma is headquartered in Denmark with a global team of 4,200 people, serving millions of patients across the world. In 2023, the company generated net sales of DKK 11.4 billion.

Contact:

Jes Broe Frederiksen
LEO Pharma, Senior Manager, Global Product and Data Communications
Tel: +45 53 60 59 48
Email: jebfe@leo-pharma.com

Melissa Borland
LEO Pharma, Senior Manager, Communications – North America
Tel: + 1 647 241 1475
Email: MQBCA@leo-pharma.com

References

1. Jonathan Silverberg, et al. Real-world effectiveness of persistent tralokinumab use on clinician and patient-reported outcomes in patients with atopic dermatitis in the CorEvitas Atopic Dermatitis Registry. Presented at the 2024 Revolutionizing Atopic Dermatitis (RAD) Conference; June 8 2024; Chicago, IL.
2. Eric Simpson, et al. Real-world baseline characteristics and persistence in adult patients initiating tralokinumab in the CorEvitas Atopic Dermatitis Registry. Presented at the 2024 Revolutionizing Atopic Dermatitis (RAD) Conference; June 8 2024; Chicago, IL.
3. Weidinger S, et al. Atopic dermatitis. Lancet. 2016;387:1109-1122.
4. Boguniewicz M, et al. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunol Rev. 2011;242(1):233-46.
5. Bieber T. Interleukin-13: targeting an underestimated cytokine in atopic dermatitis. Allergy. 2020; 75:54-62.

6. Popovic B, et al. Structural characterisation reveals mechanism of IL-13-neutralising monoclonal antibody tralokinumab as inhibition of binding to IL-13Rα1 and IL-13Rα2. J Mol Biol. 2017; 429:208-19.